A Generic Ozempic Pen Recall and What It Means for Virtual Care Patients

What Health Canada announced

Apotex recalled lot 7000636A of its Apo-Semaglutide 1 mg-dose pen (4 mg/pen) on September 23, 2026. Health Canada says pens from the lot may show, and deliver, 0.25 mg or 0.5 mg in place of 1 mg.

• Product: Apo-Semaglutide injection, 1 mg-dose pen (4 mg/pen), DIN 02568012, 1.34 mg/mL
• Affected lot: 7000636A
• Recall date: September 23, 2026 (Health Canada reference RA-82679, Type II, retail depth)
• Distribution: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Ontario and Quebec

Why it matters if you use virtual care

When medication is prescribed by video visit and delivered by mail, no pharmacist is handing you the box. Recall notices typically reach pharmacies and retailers (this one is a retail-depth recall), not necessarily the patient. Checking your own lot number is the reliable route.

What to do

• Read the lot number on the pen or carton.
• If it is 7000636A, do not stop your medication on your own; speak to your pharmacist or prescriber.
• Ask Apotex about the recall, and report side effects to Health Canada.

The same checks apply to any prescription you receive by courier, whatever the treatment.